Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease
PRX-PLUS has a unique product feature with its deep-impacting formula
This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets
Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)
Positions Curium as leading manufacturer of Lu-177 isotope
Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206 and BAT2506
New facility will support plans to advance J&J’s portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases
Adults taking Mounjaro with diet and exercise in a controlled clinical trial lost on average 21.8 kg at the highest dose (15mg) and 15.4 kg at the lowest dose (5mg)
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
Nanomi's pioneering approach in drug delivery has set new benchmarks in the industry, and this award serves as a motivation to continue its mission to revolutionize healthcare
Subscribe To Our Newsletter & Stay Updated
